VenatoRx Pharmaceuticals Revenue and Competitors

Claim your profile



Total Funding



Estimated Revenue & Valuation

  • VenatoRx Pharmaceuticals's estimated annual revenue is currently $15.5M per year.(i)
  • VenatoRx Pharmaceuticals received $42.0M in venture funding in July 2017.
  • VenatoRx Pharmaceuticals's estimated revenue per employee is $201,000
  • VenatoRx Pharmaceuticals's total funding is $107M.

Employee Data

  • VenatoRx Pharmaceuticals has 77 Employees.(i)
  • VenatoRx Pharmaceuticals grew their employee count by -4% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

Led by a world-class team of pharmaceutical veterans, VenatoRx is a private pharmaceutical company that is developing a new wave of anti-infective products to address increasing medical needs. VenatoRx's lead product, VNRX-5133, is an injectable broad-spectrum beta-lactamase inhibitor (BLI) that directly inhibits all four Ambler classes of beta-lactamases. Early clinical studies of cefepime/VNRX-5133 have been completed and VenatoRx plans to start Phase 3 pivotal trials in the second half of 2018. In addition, VenatoRx has a broad pipeline of preclinical programs, including a broad-spectrum orally bioavailable BLI, a novel class of Penicillin-Binding Protein (PBP) inhibitors that are impervious to beta-lactamase-driven resistance, and novel antiviral agents.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





VenatoRx Pharmaceuticals News

2022-03-30 - Venatorx Pharmaceuticals Raises Series C Financing

Venatorx Pharmaceuticals, Inc., a Malvern, PA-based private, clinical-stage pharmaceutical company focused on improving health outcomes for...

2022-03-30 - AMR Action Fund Announces First Investments in Adaptive ...

"Adaptive Phage Therapeutics and Venatorx Pharmaceuticals are poised to change the treatment landscape for drug-resistant infections," said AMR...

2022-03-30 - Venatorx Pharmaceuticals Raises Series C Financing Led by ...

Venatorx is a private, clinical-stage pharmaceutical company focused on improving health outcomes for patients with multidrug-resistant...

2019-09-07 - VenatoRx Pharmaceuticals Names Joseph C. Larsen, Ph.D. Vice President, Strategic Portfolio Development

MALVERN, Pa.--(BUSINESS WIRE)--. VenatoRx Pharmaceuticals today announced that Joseph C. Larsen, Ph.D. has joined the Company as ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

VenatoRx Pharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2017-07-26$42.0MBVersant VenturesArticle

VenatoRx Pharmaceuticals Executives

Tim HenkelChief Medical Officer
Tony MeehanChief Business Officer
Christopher BurnsPresident and Chief Executive Officer
Ezra FelkerChief Operating Officer
James MurphyChief Financial Officer
Daniel PevearFounder and Senior Vice President, Biology and Grants Development
Mary DorrVP of Clinical Science
Heather HunterVice President, Communications
Christopher BurnsPresident and Chief Executive Officer
Susan EmeighVice President, Non-Clinical Safety
Larry RosenVice President Pharmaceutical Product Development
Stephen CondonVice President, Chemistry
Jennifer NelsonVice President, R&D Program Management
Brian BentleyVice President Regulatory Affairs
Paul McGovernSenior Vice President Medical Sciences
Scott McConnellVice President Medical Affairs
Jennifer EllissVP Quality
Greg MoeckVice President, Microbiology
Will SargentSVP, Commercial Strategy
Chitrananda AbeygunawardanaVP, Regulatory Affairs